France urothelial carcinoma market is estimated to grow considerably, at a CAGR of around 9.6% during the forecast period. France is one of the leading economies and technologically advanced countries in Europe. France has a quality healthcare system and favorable government policies which is augmenting the growth of the market in France. The number of new cases associated with bladder cancer is less than that of other economies of the region. Bladder cancer cases accounted for nearly 3.6% of the total cases registered in 2018. In 2018, the total number of new cases of cancer were recorded to be 455,618 out of which 16,282 cases were registered for bladder cancer.
Furthermore, bladder cancer cases were registered more for men as compared to women. Furthermore, the total number of deaths caused due to bladder cancer in France was about 7,198. These figures show significant potential for the growth of the market in the near future. Moreover, The healthcare expenditure in France is high which is around 10% of the total GDP of France. Furthermore, according to French National Cancer Institute, between 2007-2016 nearly $1.05 billion were invested in research and development of cancer treatment. As this increase, it is expected to promote the growth of the market over the forecast period.
OMR Global Recently Published Report on: https://www.omrglobal.com/industry-reports/france-urothelial-carcinoma-market
Market Segmentation
France Urothelial Carcinoma Market by Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
France Urothelial Carcinoma Market by Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
To Learn More About this Report Request a Free Sample Copy @ https://www.omrglobal.com/request-sample/france-urothelial-carcinoma-market
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
